Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 6/20 | 0.69 |
| ▸ | IGF1R | P08069 | 5/20 | 0.67 |
| ▸ | JAK2 | O60674 | 4/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485399 | 0.89 | EGFR (0.72) | PLK4IGF1RJAK2JAK3EGFR | |
| SCHEMBL3214863 | 0.87 | PLK4 (0.69) | PLK4IGF1RJAK2JAK3AURKA | |
| SCHEMBL25709028 | 0.82 | IGF1R (0.76) | PLK4IGF1RJAK2JAK3AURKA | |
| SCHEMBL23906597 | 0.81 | IGF1R (0.62) | PLK4IGF1RJAK2JAK3AURKA | |
| SCHEMBL30086456 | 0.81 | IGF1R (0.62) | PLK4IGF1RJAK2JAK3AURKA | |
| SCHEMBL11340146 | 0.81 | IGF1R (1.00) | PLK4IGF1RJAK2JAK3AURKA | |
| SCHEMBL4622752 | 0.81 | AURKA (0.66) | PLK4JAK2JAK3AURKAAURKB | |
| SCHEMBL13485388 | 0.79 | JAK2 (0.77) | PLK4IGF1RJAK2JAK3EGFR | |
| Formaldehyde SCHEMBL3306379 | 0.78 | JAK2 (0.47) | PLK4IGF1RJAK2JAK3AURKA | |
| SCHEMBL29716063 | 0.78 | AURKA (0.58) | PLK4IGF1RJAK2JAK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | JAK2, JAK1, JAK3 | PLK4 565/4885IGF1R 1726/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.